Gilead Sciences could at one time do no wrong, but then sales of its hep C meds slowed and it hit some major trial setbacks. Now, the biotech faces increasingly loud questions about what its next Big Thing will be.
Although a little late to the game, AbbVie is touting impressive cure rates for its new daily hep C combo as it looks to find a bigger wedge in a market dominated by Gilead.
